Global Schizophrenia Drugs Market

Schizophrenia Drugs Market Size, Share, Growth Analysis, By Therapeutic Class(Second Generation, Third Generation, Others), By Treatment(Oral, Injectable), By Distribution channel(Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), By Region - Industry Forecast 2024-2031


Report ID: SQSG35I2011 | Region: Global | Published Date: April, 2024
Pages: 157 |Tables: 90 |Figures: 76

Schizophrenia Drugs Market Insights

Global Schizophrenia Drugs Market size was valued at USD 7.16 billion in 2019 and is poised to grow from USD 7.58 billion in 2023 to USD 12.58 billion by 2031, growing at a CAGR of 5.8% in the forecast period (2024-2031).

Significant suffering and impairment in essential facets of one's life, including those related to the self, the family, the community, education, employment, and others, are typical symptoms of schizophrenia.

Schizophrenia patients have a two to three times higher risk of dying young than the general population.  Physical ailments like the cardiovascular, metabolic, and frequent occurrence of infectious diseases. Schizophrenia affects approximately 24 million people or 1 in 300 people (0.32%) worldwide. This rate is 1 in 222 people (0.45%) among adults (2). It is not as common as many other mental disorders. Schizophrenia is diagnosed 1.4 times more frequently in males than females, as the onset is earlier in men. The peak age of onset is 20–28 years for males and 25–32 years for females.

India and China are starting to present opportunities for market growth. The main driving forces for market expansion in these two countries are elements like advantageous healthcare reforms, a rising aging population, improved health awareness, and a low-cost basis., thereby supporting the growth of the market in the Asia Pacific region. While the lack of awareness in underdeveloped countries is the limiting factor to the growth of the market.

US Schizophrenia Drugs Market is poised to grow at a sustainable CAGR for the next forecast year.

Market Snapshot - 2024-2031

Global Market Size

USD 7.16 billion

Largest Segment

Injectable

Fastest Growth

Injectable

Growth Rate

5.8% CAGR

Global Schizophrenia Drugs Market 2021-2028 ($ Bn)
Country Share for North America Region- 2021 (%)

To get more reports on the above market click here to Buy The Report

Schizophrenia Drugs Market Segmental Analysis

Schizophrenia Drugs Market is segmented based on therapeutic class, treatment, distribution channel, and Region. Based on the therapeutic class the Global schizophrenia drugs market is segmented as Second Generation, Third Generation, and Others. Based on treatment, the Global schizophrenia drugs Market is segmented as Oral and Injectable. Based on the distribution channel, the Global schizophrenia drugs Market is segmented as Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others. Based on Region Schizophrenia Drugs Market is categorized into North America, Europe, Asia-Pacific, South America, and MEA.

Schizophrenia Drugs Market Analysis by Therapeutic Class

Based on the therapeutic class the Global schizophrenia drugs market is segmented as Second Generation, Third Generation, and Others. Based on therapeutic class, the second and third-generation anti-psychotics segments are the preferred therapy line for schizophrenia due to greater development in delivering various benefits like improved treatment outcomes and fewer hospitalizations. The factors influencing schizophrenia medications include the increase in the elderly population and product approvals.

Schizophrenia Drugs Market Analysis by Treatment

Based on treatment, the Global schizophrenia drugs Market is segmented as Oral and Injectable. According to treatment, the injectable antipsychotics segment is dominating the market for schizophrenia treatments. Due to increased adherence and more consistent pharmacokinetics, long-acting injectable antipsychotics are more effective and tolerable. Combining injectable antipsychotics with high-quality psychosocial care will lower the probability of relapse in schizophrenia outpatients.

Schizophrenia Drugs Market Analysis by Distribution channel

Based on the distribution channel, the Global schizophrenia drugs Market is segmented as Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others. The hospital pharmacies segment is predicted to be the most dominant sector in the distribution channel segment, in part because major psychiatrists continue to practice in major hospitals and in part because long-acting injectables are becoming more popular, which the doctors may use in their everyday work. Next comes the online pharmacies segment with the convenient method of availability of medicines growing at a steady pace following the growth of hospital pharmacies.

Global Schizophrenia Drugs Market By Treatment, 2021 (%), 2023 (%)

To get detailed analysis on other segments, Request For Free Sample Report

Schizophrenia Drugs Market Regional Insights

Global schizophrenia drugs market is dominated by Asia pacific region. Many manufacturers on the market are concentrating on research and development efforts to create safer and more effective medications to treat mental disorders. Key players are also attempting to enter into agreements, colorations, and acquisitions to broaden their product range in order to meet the soaring demand for anti-anxiety and anti-depression medications.

For instance, an Indian multinational pharmaceutical company named Sun Pharmaceutical Industries Ltd. announced in 2022 that it had entered into a licensing agreement with a pharmaceutical company based in Denmark to introduce cutting-edge anti-depression medications under the trade name Vortidiftm in India. Numerous of these changes are predicted to benefit the market for psychotropic medications in the Asia Pacific except in China and Japan. In the region of North America, the market is lately been in a declining phase because of decreasing demand for schizophrenia drugs.

Global Schizophrenia Drugs Market By Geography, 2021 - 2028, 2024-2031
  • Largest
  • Fastest

To know more about the market opportunities by region and country, click here to
Buy The Complete Report

Schizophrenia Drugs Market Dynamics

Schizophrenia Drugs Market Driver

  • The market is anticipated to be driven by an increase in the number of patients receiving treatment and a rising desire for better healthcare infrastructure. In recent years, governments in multiple nations have worked successfully with numerous hospitals to provide better safety for those who suffer from schizophrenia. The market under study is expanding as a result of the growing illness load and the growing need to properly control it.
  • Clinical studies for several products are now being conducted to treat schizophrenia. It is anticipated that some of the medications will target novel molecular targets to address the disorder's unmet medical needs. It is anticipated that a number of market participants will try to fill unmet consumer requirements, find new targets, and subsequently build stronger medication pipelines.

Schizophrenia Drugs Market Restraint

  • The Schizophrenia Market is dealing with issues that are impacting the market at a time when it is expanding. The market is being challenged by the lack of sufficient understanding of the risk of mental health issues in poor nations. Making individuals aware of effective treatments and getting their attention are difficult to market considerations due to a lack of appropriate sources.
  • The expansion of the schizophrenia market is being hampered by some factors. The increased expense of the drug and treatment is restricting the market. The adverse effects of the medications created to treat schizophrenia have an impact on the market's growth rate.

Request Free Customization of this report to help us to meet your business objectives.

Schizophrenia Drugs Market Competitive Landscape

There is huge competition in the global Schizophrenia drugs Market. The prominent players operating in the market are constantly adopting various growth strategies to stay afloat in the market. Product launches, innovations, mergers, and acquisitions, collaborations and partnerships, and product differentiation are some of the growth strategies that are adopted by these key players to thrive in the competitive market.

Schizophrenia Drugs Market Top Players Company Profiles

  • Otsuka Pharmaceutical
  • Johnson & Johnson
  • Eli Lilly and Company
  • AstraZeneca
  • Pfizer
  • Bristol-Myers Squibb
  • Allergan
  • Sumitomo Dainippon Pharma
  • Lundbeck
  • Alkermes
  • Vanda Pharmaceuticals
  • Intra-Cellular Therapies
  • ACADIA Pharmaceuticals
  • Sunovion Pharmaceuticals
  • Neurocrine Biosciences
  • Takeda Pharmaceutical
  • H. Lundbeck A/S
  • Recordati S.p.A.
  • Reviva Pharmaceuticals Inc.
  • Minerva Neurosciences Inc.

Schizophrenia Drugs Market Recent Developments

  • In June 2022, Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system (CNS), announced encouraging interim results from the first 100 patients in its world-first, international, six-week, open-label, randomized, rater-blinded, multi-center study of evenamide as an add-on to an antipsychotic in patients with moderate to severe treatment-resistant schizophrenia (TRS) who were not responding to current antipsychotic medication.
  • In April 2022, Saladax Biomedical, Inc. (Saladax) is pleased to announce that it has acquired a patent portfolio for antipsychotic drug testing from Janssen Pharmaceutica NV. This intellectual property (IP) portfolio includes 17 patent families and has resulted in 33 U.S. patents and 296 patents in ex-U.S. countries. This IP, along with the current Saladax IP, covers the major antipsychotic drugs that are prescribed worldwide and places Saladax in a premier position in the antipsychotic drug testing field.

Schizophrenia Drugs Key Market Trends

  • The mechanisms behind schizophrenia, which were formerly considered to be related to excessive presynaptic dopamine in certain parts of the brain, are now known to be far more complicated, involving structural and chemical abnormalities throughout brain circuits. As a result, drug development efforts have pursued new targets in the search for safer and more effective drugs to treat schizophrenia and psychosis, such as trace amine-associated receptors (TAARs), muscarinic receptors, and serotonergic receptors.

Schizophrenia Drugs Market SkyQuest Analysis

SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Co-relates, and Analyses the Data collected utilizing Primary Exploratory Research backed by the robust Secondary Desk research.

According to our Global Schizophrenia drugs Market Analysis, Asia pacific has dominated the market due to many manufacturers on the market are concentrating on research and development efforts to create safer and more effective medications to treat mental disorders. Key players are also attempting to enter into agreements, colorations, and acquisitions to broaden their product range in order to meet the soaring demand for anti-anxiety and anti-depression medications. Among segments, the second and third-generation therapeutics are expected to capture a larger market share in the future whereas the segment of injectable antipsychotics segment is dominating the market for schizophrenia treatments. Due to increased adherence and more consistent pharmacokinetics, long-acting injectable antipsychotics are more effective and tolerable. The market growth is been favored by the rising demand of antipsychotic drugs. Factor such as higher costs and lack of awareness about mental disorders are restraining the growth of market.

Report Metric Details
Market size value in 2023 USD 7.16 billion
Market size value in 2031 USD 12.58 billion
Growth Rate 5.8%
Forecast period 2024-2031
Forecast Unit (Value) USD Billion
Segments covered
  • Therapeutic Class
    • Second Generation, Third Generation, Others
  • Treatment
    • Oral, Injectable
  • Distribution channel
    • Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others
Regions covered North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA)
Companies covered
  • Otsuka Pharmaceutical
  • Johnson & Johnson
  • Eli Lilly and Company
  • AstraZeneca
  • Pfizer
  • Bristol-Myers Squibb
  • Allergan
  • Sumitomo Dainippon Pharma
  • Lundbeck
  • Alkermes
  • Vanda Pharmaceuticals
  • Intra-Cellular Therapies
  • ACADIA Pharmaceuticals
  • Sunovion Pharmaceuticals
  • Neurocrine Biosciences
  • Takeda Pharmaceutical
  • H. Lundbeck A/S
  • Recordati S.p.A.
  • Reviva Pharmaceuticals Inc.
  • Minerva Neurosciences Inc.
Customization scope

Free report customization with purchase. Customization includes:-

  • Segments by type, application, etc
  • Company profile
  • Market dynamics & outlook
  • Region

Historical Year 2019

To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.

Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share

Table Of Content

Executive Summary

Market overview

  • Exhibit: Executive Summary – Chart on Market Overview
  • Exhibit: Executive Summary – Data Table on Market Overview
  • Exhibit: Executive Summary – Chart on Schizophrenia Drugs Market Characteristics
  • Exhibit: Executive Summary – Chart on Market by Geography
  • Exhibit: Executive Summary – Chart on Market Segmentation
  • Exhibit: Executive Summary – Chart on Incremental Growth
  • Exhibit: Executive Summary – Data Table on Incremental Growth
  • Exhibit: Executive Summary – Chart on Vendor Market Positioning

Parent Market Analysis

Market overview

Market size

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • SWOT Analysis

KEY MARKET INSIGHTS

  • Technology Analysis
    • (Exhibit: Data Table: Name of technology and details)
  • Pricing Analysis
    • (Exhibit: Data Table: Name of technology and pricing details)
  • Supply Chain Analysis
    • (Exhibit: Detailed Supply Chain Presentation)
  • Value Chain Analysis
    • (Exhibit: Detailed Value Chain Presentation)
  • Ecosystem Of the Market
    • Exhibit: Parent Market Ecosystem Market Analysis
    • Exhibit: Market Characteristics of Parent Market
  • IP Analysis
    • (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
  • Trade Analysis
    • (Exhibit: Data Table: Import and Export data details)
  • Startup Analysis
    • (Exhibit: Data Table: Emerging startups details)
  • Raw Material Analysis
    • (Exhibit: Data Table: Mapping of key raw materials)
  • Innovation Matrix
    • (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
  • Pipeline product Analysis
    • (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
  • Macroeconomic Indicators

COVID IMPACT

  • Introduction
  • Impact On Economy—scenario Assessment
    • Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
  • Revised Market Size
    • Exhibit: Data Table on Schizophrenia Drugs Market size and forecast 2021-2027 ($ million)
  • Impact Of COVID On Key Segments
    • Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
  • COVID Strategies By Company
    • Exhibit: Analysis on key strategies adopted by companies

MARKET DYNAMICS & OUTLOOK

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • Regulatory Landscape
    • Exhibit: Data Table on regulation from different region
  • SWOT Analysis
  • Porters Analysis
    • Competitive rivalry
      • Exhibit: Competitive rivalry Impact of key factors, 2021
    • Threat of substitute products
      • Exhibit: Threat of Substitute Products Impact of key factors, 2021
    • Bargaining power of buyers
      • Exhibit: buyers bargaining power Impact of key factors, 2021
    • Threat of new entrants
      • Exhibit: Threat of new entrants Impact of key factors, 2021
    • Bargaining power of suppliers
      • Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
  • Skyquest special insights on future disruptions
    • Political Impact
    • Economic impact
    • Social Impact
    • Technical Impact
    • Environmental Impact
    • Legal Impact

Market Size by Region

  • Chart on Market share by geography 2021-2027 (%)
  • Data Table on Market share by geography 2021-2027(%)
  • North America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • USA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Canada
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Europe
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Germany
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Spain
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • France
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • UK
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Europe
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Asia Pacific
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • China
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • India
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Japan
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Korea
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Asia Pacific
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Latin America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Brazil
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of South America
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Middle East & Africa (MEA)
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • GCC Countries
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Africa
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of MEA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)

KEY COMPANY PROFILES

  • Competitive Landscape
    • Total number of companies covered
      • Exhibit: companies covered in the report, 2021
    • Top companies market positioning
      • Exhibit: company positioning matrix, 2021
    • Top companies market Share
      • Exhibit: Pie chart analysis on company market share, 2021(%)

Methodology

For the Schizophrenia Drugs Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:

1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.

2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Schizophrenia Drugs Market.

3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.

4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.

Analyst Support

Customization Options

With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Schizophrenia Drugs Market:

Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.

Regional Analysis: Further analysis of the Schizophrenia Drugs Market for additional countries.

Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.

Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.

Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.

Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.

Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.

Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Schizophrenia Drugs Market size was valued at USD 7.16 billion in 2019 and is poised to grow from USD 7.58 billion in 2023 to USD 12.58 billion by 2031, growing at a CAGR of 5.8% in the forecast period (2024-2031).

There is huge competition in the Schizophrenia drugs Market. The prominent players operating in the market are constantly adopting various growth strategies to stay afloat in the market. Product launches, innovations, mergers, and acquisitions, collaborations and partnerships, and product differentiation are some of the growth strategies that are adopted by these key players to thrive in the competitive market. 'Otsuka Pharmaceutical', 'Johnson & Johnson', 'Eli Lilly and Company', 'AstraZeneca', 'Pfizer', 'Bristol-Myers Squibb', 'Allergan', 'Sumitomo Dainippon Pharma', 'Lundbeck', 'Alkermes', 'Vanda Pharmaceuticals', 'Intra-Cellular Therapies', 'ACADIA Pharmaceuticals', 'Sunovion Pharmaceuticals', 'Neurocrine Biosciences', 'Takeda Pharmaceutical', 'H. Lundbeck A/S', 'Recordati S.p.A.', 'Reviva Pharmaceuticals Inc.', 'Minerva Neurosciences Inc.'

The market is anticipated to be driven by an increase in the number of patients receiving treatment and a rising desire for better healthcare infrastructure. In recent years, governments in multiple nations have worked successfully with numerous hospitals to provide better safety for those who suffer from schizophrenia. The market under study is expanding as a result of the growing illness load and the growing need to properly control it.

The mechanisms behind schizophrenia, which were formerly considered to be related to excessive presynaptic dopamine in certain parts of the brain, are now known to be far more complicated, involving structural and chemical abnormalities throughout brain circuits. As a result, drug development efforts have pursued new targets in the search for safer and more effective drugs to treat schizophrenia and psychosis, such as trace amine-associated receptors (TAARs), muscarinic receptors, and serotonergic receptors.

schizophrenia drugs market is dominated by Asia pacific region. Many manufacturers on the market are concentrating on research and development efforts to create safer and more effective medications to treat mental disorders. Key players are also attempting to enter into agreements, colorations, and acquisitions to broaden their product range in order to meet the soaring demand for anti-anxiety and anti-depression medications.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Schizophrenia Drugs Market

Product ID: SQSG35I2011

$5,300
BUY NOW GET FREE SAMPLE